Related Experiment Video
Updated: May 30, 2026
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
[Do disease modifying drugs exist for osteoarthritis].
Rolando Espinosa Morales1, María Esther Pérez Bastidas
1Departamento de Reumatología. Instituto Nacional de Rehabilitación. México DF. México.
Reumatologia Clinica
|July 29, 2011
Summary
New osteoarthritis drugs show potential for modifying disease progression by reducing inflammation and protecting cartilage. Clinical studies confirm symptom relief and improved joint function, offering hope for better long-term outcomes.
Area of Science:
- Rheumatology and Pharmacology
- Biochemistry and Molecular Biology
Context:
- Osteoarthritis (OA) poses significant epidemiological, social, and economic burdens.
- Current OA treatments primarily manage pain and inflammation.
- Emerging drugs offer potential disease-modifying effects beyond symptom relief.
Purpose:
- To explore novel in vitro mechanisms of action for new OA drugs.
- To review clinical evidence supporting the efficacy of these drugs.
- To assess their potential to modify the natural history of osteoarthritis.
Summary:
- New drugs demonstrate in vitro mechanisms targeting proinflammatory cytokines and matrix metalloproteinases, crucial in cartilage degradation.
- These agents also exhibit anti-apoptotic effects on chondrocytes, preserving joint tissue.
- Clinical trials show efficacy in reducing pain and enhancing joint function, with some evidence suggesting preservation of joint space.
Impact:
- These advancements may lead to treatments that slow or halt osteoarthritis progression.
- Potential to reduce the long-term burden of osteoarthritis on patients and healthcare systems.
- Offers a paradigm shift from purely symptomatic management to disease modification in osteoarthritis care.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.